

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **VELTASSA**[®]

Patiromer Powder for Oral Suspension

8.4 g, 16.8 g, 25.2 g patiromer (as patiromer sorbitex calcium)

Potassium Binder (ATC Code: V03AE09)

Vifor Fresenius Medical Care Renal Pharma Ltd.
Rechenstrasse 37, 9014 St. Gallen
Switzerland

Imported and Distributed by:
Otsuka Canada Pharmaceutical Inc.
Saint-Laurent, Quebec, H4S 2C9

Date of Initial Approval:
October 3, 2018

Date of Revision:
February 28, 2020

Submission Control No: 229946

RECENT MAJOR LABEL CHANGES

Not applicable.

TABLE OF CONTENTS

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
3 DOSAGE AND ADMINISTRATION	4
3.1 Dosing Considerations.....	4
3.2 Recommended Dose and Dosage Adjustment	4
3.3 Administration	5
3.4 Reconstitution.....	5
3.5 Missed Dose	5
4 OVERDOSAGE	5
5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	6
6 WARNINGS AND PRECAUTIONS	6
6.1 Special Populations	7
6.1.1 Pregnant Women.....	7
6.1.2 Breast-feeding	8
6.1.3 Pediatrics.....	8
7 ADVERSE REACTIONS	8
7.1 Adverse Reaction Overview	8
7.2 Clinical Trial Adverse Reactions.....	8
7.3 Less Common Clinical Trial Adverse Reactions (<1%)	10
7.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	10
7.5 Post-Market Adverse Reactions	10
8 DRUG INTERACTIONS	11
8.1 Overview	11
8.2 Drug-Drug Interactions	11
8.3 Drug-Food Interactions	12
8.4 Drug-Herb Interactions.....	12
8.5 Drug-Laboratory Test Interactions	12
9 ACTION AND CLINICAL PHARMACOLOGY	12

9.1	Mechanism of Action	12
9.2	Pharmacodynamics.....	13
9.3	Pharmacokinetics.....	14
10	STORAGE, STABILITY AND DISPOSAL	14
11	SPECIAL HANDLING INSTRUCTIONS	14
12	PHARMACEUTICAL INFORMATION	15
13	CLINICAL TRIALS	16
13.1	Trial Design and Study Demographics.....	16
13.2	Study Results	18
14	NON-CLINICAL TOXICOLOGY	20
	PATIENT MEDICATION INFORMATION	22

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Veltassa (patiromer as patiromer sorbitex calcium) is indicated for:

- the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥ 15 mL/min/1.73m²).

1.1 Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is not associated with significant differences in safety or efficacy.

2 CONTRAINDICATIONS

Veltassa is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [Dosage Forms, Strengths, Composition and Packaging](#).

Patients with the rare hereditary condition of fructose intolerance

- Sorbitol: Veltassa contains approximately 11 g of sorbitol per maximum recommended daily dose.

3 DOSAGE AND ADMINISTRATION

3.1 Dosing Considerations

- The onset of action of Veltassa occurs 4 – 7 hours after administration. Veltassa should not replace emergency treatment for life threatening hyperkalemia due to its delayed onset of action.
- Administration of Veltassa should be separated by 3 hours from other oral medicinal products (see [Drug-Drug Interactions](#)).
- Monitor serum potassium, and adjust the dose of Veltassa based on the desired target range (see Recommended Dose and Dosage Adjustment), or after changes are made to medicinal products that affect serum potassium levels (see Warnings and Precautions).
- There are limited data on the use of Veltassa in patients on dialysis. No special dose and administration guidelines were applied to these patients in clinical studies.

3.2 Recommended Dose and Dosage Adjustment

The recommended starting dose of Veltassa is 8.4 g patiromer once daily.

The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g once daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.

Health Canada has not authorized an indication for pediatric use.

3.3 Administration

Oral use. Veltassa must be suspended in a liquid prior to administration (see Reconstitution). Veltassa may be taken with or without food. It should not be heated (e.g., microwaved) or added to hot foods or liquids. It should not be taken in its dry form.

3.4 Reconstitution

Veltassa should be mixed with water and stirred to a suspension of uniform consistency, according to the following steps:

- The complete dose should be poured into a glass containing approximately 40 mL of water, then stirred.
- Another approximately 40 mL of water should be added, and the suspension stirred again thoroughly. The powder will not dissolve.
- More water may be added to the mixture as needed for desired consistency.
- The mixture should be taken within 1 hour of initial suspension.
- If powder remains in the glass after drinking, more water should be added and the suspension stirred and taken immediately. This may be repeated as needed to ensure the entire dose is administered.

Apple juice or cranberry juice can be used instead of water to prepare the mixture. Other liquids should be avoided as they may contain high amounts of potassium.

3.5 Missed Dose

If a dose is missed, the missed dose should be taken as soon as possible on the same day. The missed dose should not be taken with the next dose.

4 OVERDOSAGE

Since excessive doses of Veltassa may result in hypokalemia, serum potassium levels should be monitored. Patiromer is excreted after approximately 24 to 48 hours, based on average gastrointestinal transit time. If it is determined that medical intervention is required, appropriate measures to restore serum potassium may be considered. Doses of Veltassa in excess of 50.4 g patiromer per day have not been tested.

For management of a suspected drug overdose, contact your regional poison control centre.

5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Powder for oral suspension Sachets containing 8.4 g, 16.8 g, or 25.2 g patiromer (as patiromer sorbitex calcium)	Xanthan gum

Veltassa includes sorbitol and calcium as part of the drug substance.

Veltassa 8.4 g powder for oral suspension is supplied in 80 x 130 mm sachets.

Veltassa 16.8 and 25.2 g powder for oral suspension is supplied in 90 x 165 mm sachets.

Veltassa is supplied in boxes of 30 sachets. The 8.4g is also available in boxes of 4 sachets.

6 WARNINGS AND PRECAUTIONS

General

There is limited clinical trial experience in patients with serum potassium concentrations greater than 6.5 mmol/L.

Driving and Operating Machinery

Veltassa does not impair the ability to drive a motor vehicle or operate machinery.

Gastrointestinal

Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies. Gastrointestinal ischemia, necrosis and/or intestinal perforation have been reported with other potassium binders. The benefits and risks of administering Veltassa should be carefully evaluated in patients with current or history of severe gastrointestinal disorders, before and during treatment.

Hepatic/Biliary/Pancreatic

No data in patients with hepatic impairment are available.

Monitoring and Laboratory Tests

Serum Potassium Levels and potential for hypokalemia

Serum potassium should be monitored when clinically indicated, including after changes are made to medicinal products that affect the serum potassium concentration (e.g., renin-aldosterone-angiotensin-system inhibitors [RAASi] or diuretics) and after the Veltassa dose is titrated.

Veltassa binds to potassium in the gastrointestinal-tract, which can lead to hypokalemia. In pooled safety data from four clinical trials, 5% of patients treated with Veltassa developed a serum potassium value of <3.5 mmol/L (rates were lower in studies that used individualised dose titration), with none <3.0 mmol/L. Lower the dose of Veltassa, or discontinue use, if serum potassium levels decrease below 3.5 mmol/L or the desired target range.

Potential for Hyperkalemia on Discontinuation

When discontinuing Veltassa, serum potassium levels may rise, especially if renin-angiotensin-aldosterone system inhibitor (RAASi) treatment is continued. Patients should be instructed not to discontinue therapy without consulting their physicians. Increases in serum potassium may occur as early as 2 days after the last Veltassa dose.

Hypomagnesemia

Veltassa binds to magnesium in the gastrointestinal-tract, which can lead to hypomagnesemia. In pooled safety data from four clinical trials, serum magnesium values <0.58 mmol/L occurred in 9% of patients treated with Veltassa, with no patients developing a serum magnesium level <0.4 mmol/L. Mean decreases in serum magnesium were 0.070 mmol/L or less. Serum magnesium should be monitored for at least 1 month after initiating treatment, and magnesium supplementation considered in patients who develop low serum magnesium levels.

Calcium levels

Veltassa contains calcium as part of the counterion complex. Calcium is partially released and some may be absorbed (see [Pharmacodynamics](#)). The benefits and risks of administering Veltassa should be carefully evaluated in patients at risk of hypercalcaemia. Calcium supplementation is not recommended in patients taking Veltassa.

Renal

The safety and efficacy of Veltassa were demonstrated in hyperkalemic patients, 93% of whom had chronic kidney disease (CKD). Veltassa has been studied in only a limited number of patients with end-stage renal disease (ESRD) with estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m² and patients receiving dialysis treatment.

Sexual Health

Fertility

There are no data on the effect of Veltassa on fertility in humans. Short-term animal studies showed no effects on reproductive function or fertility (see [NON-CLINICAL TOXICOLOGY](#)).

6.1 Special Populations

6.1.1 Pregnant Women

There are no adequate and well-controlled studies on the use of patiromer in pregnant women. Although systemic exposure to Veltassa is negligible, it is unknown whether the drug has potential for indirect harm to the fetus. Veltassa is known to influence serum levels of electrolytes (e.g. potassium, magnesium, potentially calcium), and may interact with the absorption of vitamins (e.g. thiamine; see Drug-Drug Interactions). This may impact the development of a fetus. Data obtained from animal studies did not conclusively show the

absence of effects on fetal health (see NON-CLINICAL TOXICOLOGY). Hence, the use of Veltassa during pregnancy is not recommended.

6.1.2 Breast-feeding

There have been no adequate, well-controlled studies in nursing women; however, since the systemic exposure of the breast-feeding woman to patiromer is negligible, excretion of patiromer from Veltassa in breast milk is unlikely. Nonetheless, as Veltassa is known to influence serum levels of electrolytes (e.g. potassium, magnesium, potentially calcium) and may interact with the absorption of vitamins (e.g. thiamine) that are important for the developing infant, caution should be exercised if Veltassa is to be used in nursing women.

6.1.3 Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

7 ADVERSE REACTIONS

7.1 Adverse Reaction Overview

The majority of the adverse reactions (ARs) reported from trials (based on a pooled safety population of 666 patients) were gastrointestinal disorders and hypomagnesemia. Gastrointestinal disorder reactions were generally mild to moderate in nature, generally resolved spontaneously or with treatment, and none were reported as serious. Hypomagnesemia was mild to moderate, with no patient developing a serum magnesium level <0.4 mmol/L.

7.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In the safety and efficacy clinical trials, 666 adult patients received at least one dose of Veltassa, including 219 exposed for at least 6 months and 149 exposed for at least one year. [Table 2](#) provides a summary of the most common adverse reactions (occurring in $\geq 1\%$ of patients) assessed by investigators as related to Veltassa in these clinical trials. Most adverse reactions were mild to moderate, and occurred within the first 4 weeks of treatment.

Table 2 – Adverse Reactions Reported in ≥ 1% of Patients, safety population

System Organ Class	Adverse Reactions	Patients treated with Veltassa (N=666)
Gastrointestinal disorders	Constipation	6.2%
	Diarrhea	3.0%
	Abdominal pain	2.9%
	Flatulence	1.8%
Metabolism and nutrition disorders	Hypomagnesemia	5.3%
	Hypokalemia	1.5%

In the placebo controlled study RLY5016-202, the ability of Veltassa to enable concomitant spironolactone treatment was investigated in a randomised, double-blind, placebo-controlled study in heart failure patients. Patients initiated spironolactone at 25 mg/day at the same time as their randomised treatment (25.2 g patiromer daily as a divided dose or placebo), and spironolactone was up-titrated to 50 mg/day after Day 14 if serum potassium was >3.5 and ≤5.1 mmol/L. Veltassa dose was not titrated in this study. [Table 3](#) provides a summary of the most common adverse events (occurring in ≥ 1% of patients) described by investigator as related to study treatment (Veltassa or placebo) in patients in this clinical trial.

Table 3 – Adverse Events Related to Study Treatment in ≥ 1% of Patients, Study RLY5016-202

System Organ Class	Adverse Reactions	Patients treated with Veltassa (N=56)	Patients treated with Placebo (N=49)
Gastrointestinal disorders	Flatulence	7.1%	0
	Diarrhea	5.4%	2.0%
	Constipation	5.4%	0
	Vomiting	3.6%	0
	Faecal incontinence	0	2.0%
	Nausea	0	2.0%
	Abdominal discomfort	1.8%	0
	Abdominal pain	1.8%	0
	Epigastric discomfort	1.8%	0
	Frequent bowel movements	1.8%	0
Immune System Disorders	Allergic oedema	1.8%	0
Investigations	Blood lactate dehydrogenase increased	0	2.0%
Metabolism and nutrition disorders	Hypokalemia	7.1%	0

System Organ Class	Adverse Reactions	Patients treated with Veltassa (N=56)	Patients treated with Placebo (N=49)
Renal and Urinary Disorders	Renal impairment	0	4.1%
	Renal failure acute	1.8%	0
Skin and Subcutaneous Tissue Disorders	Urticaria	0	2.0%

7.3 Less Common Clinical Trial Adverse Reactions (<1%)

Adverse reactions occurring at a frequency of <1% in the pooled safety population of 666 patients are listed below:

Gastrointestinal disorders: Abdominal distension, dry mouth, dyspepsia, epigastric discomfort, gastroesophageal reflux disease, nausea, vomiting

Immune system disorders: Allergic edema, hypersensitivity

Investigations: Blood iron decreased, blood phosphorus decreased, blood pressure decreased

Metabolism and nutrition disorders: Anorexia

Musculoskeletal and connective tissue disorders: Muscle spasms

Nervous system disorders: Dysgeusia

Skin and subcutaneous tissue disorders: Pruritus

7.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Table 4 – Abnormal Laboratory Findings: Clinical Chemistry

		Patients treated with Veltassa (N=666)
Serum magnesium	Mean change	-0.067 mmol/L (-0.162 mg/dL)
	Values <0.58 mmol/L (1.4 mg/dL)	9%
	Values <0.4 mmol/L (1.0 mg/dL)	0%
Serum potassium	Mean change	-0.72 mmol/L
	Values <3.5 mmol/L	4.7%
	Values <3.0 mmol/L	0%

For more information on hypokalemia or hypomagnesemia, refer to [Warnings and Precautions](#).

7.5 Post-Market Adverse Reactions

No post-marketing experience influencing the ADR profile to date.

8 DRUG INTERACTIONS

8.1 Overview

Binding of Veltassa to some other oral medications could decrease their gastrointestinal absorption when taken close to the time of Veltassa administration. When taken 3 hours apart, no interaction was observed in drug-drug interaction clinical trials. Other oral medications should be administered at least 3 hours before or 3 hours after Veltassa (see [Dosing Considerations](#)).

8.2 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 5 – Established or Potential Drug-Drug Interactions

Common name	Source of Evidence	Effect	Clinical comment
Ciprofloxacin	CT	Veltassa decreased the systemic exposure of co-administered ciprofloxacin by 28% based on AUC. However, there was no interaction when taken 3 hours apart.	Administration of Veltassa should be separated by 3 hours from other oral medicinal products.
Levothyroxine	CT	Veltassa decreased the systemic exposure of co-administered levothyroxine by 19% based on AUC. However, there was no interaction taken 3 hours apart.	Administration of Veltassa should be separated by 3 hours from other oral medicinal products.
Metformin	CT	Veltassa decreased the systemic exposure of co-administered metformin by 19% based on AUC. However, there was no interaction when taken 3 hours apart.	Administration of Veltassa should be separated by 3 hours from other oral medicinal products.
Quinidine	T	<i>In vitro</i> studies have shown potential interaction of Veltassa with quinidine. An interaction has not been confirmed in clinical studies.	Administration of Veltassa should be separated by 3 hours from other oral medicinal products.

Common name	Source of Evidence	Effect	Clinical comment
Thiamine	T	<i>In vitro</i> studies have shown potential interaction of Veltassa with thiamine. An interaction has not been confirmed in clinical studies.	Administration of Veltassa should be separated by 3 hours from other oral medicinal products.

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

According to *in vitro* drug binding studies performed in biologically relevant matrices, the following drugs did not exhibit an *in vitro* interaction with Veltassa: acetylsalicylic acid, allopurinol, amoxicillin, apixaban, atorvastatin, cephalexin, digoxin, glipizide, lisinopril, phenytoin, riboflavin, rivaroxaban, spironolactone, and valsartan.

The following drugs showed an *in vitro* interaction with Veltassa, and it was subsequently found that Veltassa did not alter their systemic exposure as measured by the area under the curve (AUC) when co-administered with Veltassa in healthy volunteers: amlodipine, cinacalcet, clopidogrel, furosemide, lithium, metoprolol, trimethoprim, verapamil, and warfarin.

8.3 Drug-Food Interactions

Interactions with specific foods have not been established.

In an open-label study, 114 patients with hyperkalemia were treated with Veltassa (8.4 g/day initiation dose) once daily, and were randomized to receive the treatment with food or without food for 4 weeks. Veltassa dose was individually titrated. The mean daily dose of Veltassa, overall safety profile, and mean reduction from baseline in serum potassium were similar whether the patients were taking Veltassa with food or without food.

8.4 Drug-Herb Interactions

Interactions with herbal products have not been established.

8.5 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

9 ACTION AND CLINICAL PHARMACOLOGY

9.1 Mechanism of Action

Veltassa is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol complex as a counterion.

Veltassa increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.

9.2 Pharmacodynamics

In healthy adult subjects, Veltassa caused a dose-dependent increase in fecal potassium excretion, and a corresponding decrease in urinary potassium excretion with no change in serum potassium. In a Phase 1, open-label, multiple-dose crossover study in 12 healthy subjects, 25.2 g of patiromer administered once daily for 6 days resulted in a mean increase in fecal potassium excretion of 1283 mg/day, and a mean decrease in urinary potassium excretion of 1438 mg/day. Daily urinary calcium excretion increased from baseline by 53 mg/day.

In an open-label study to assess the time to onset of action, 25 patients with hyperkalemia (mean baseline serum potassium of 5.9 mmol/L) and chronic kidney disease were given 16.8 grams of patiromer daily (as divided doses) with a controlled potassium diet. A statistically significant reduction from baseline in serum potassium (-0.2 mmol/L) was observed at 7 hours after the first dose. Serum potassium levels continued to decline during the 48-hour treatment period (-0.8 mmol/L at 48 hours after the first dose). Following discontinuation of Veltassa, potassium levels remained stable for 24 hours after the last dose, then rose again during a 4-day observation period.

Electrocardiography

As patiromer is a non-absorbed polymer, no formal clinical studies were performed to assess the drug effect on prolongation of the QT interval corrected for heart rate (QTc).

Small fluctuations around the baseline mean values for heart rate, RR interval, PR interval, QRS interval, QT interval and QTcF interval were observed in pooled safety data for subjects treated with Veltassa in clinical trials; however, the fluctuations likely reflect the inherent biologic variability in cardiac conduction or repolarization over time in a subject population with a high background rate of cardiac conditions, rather than an association with Veltassa treatment. No trends were observed and there is no indication of drug-related cardiac conduction or repolarization abnormalities.

In Phase 1 studies in healthy volunteers, no dose-related changes from baseline were observed in mean QT or QT corrected according to the method of Fridericia (QTcF) intervals after single or multiple doses of Veltassa and no clinically significant changes from baseline were observed in QT or QTcF intervals after once daily (QD), twice daily (BID) or three times daily (TID) dosing.

In a double-blind, placebo-controlled Phase 2 study in subjects with heart failure, no clinically significant changes from baseline in mean RR or QT intervals were observed in the Veltassa or placebo groups, and the percentage of subjects with QTcF intervals > 470 msec was similar (8.0 and 9.5%, respectively). The proportions of subjects with QTcF intervals > 470 msec and > 500 msec remained the same in both treatment groups at every time point through Day 28 and at the last available on-study measurement.

9.3 Pharmacokinetics

Patiromer works by binding potassium in the gastrointestinal tract and thus the serum concentration is not relevant for its efficacy. Due to the insolubility and non-absorptive characteristics of this medicinal product, many classical pharmacokinetic studies cannot be carried out, e.g., determination of the distribution volume, area under the curve, mean residence time, etc.

Absorption: In radiolabelled absorption, distribution, metabolism, elimination (ADME) studies in rats and dogs, patiromer was not systemically absorbed.

Distribution: Quantitative whole-body autoradiography analysis in rats demonstrated that radioactivity was limited to the gastrointestinal tract, with no detectable level of radioactivity in any other tissues or organs.

Metabolism: Not applicable due to the insolubility and non-absorptive characteristics of patiromer.

Elimination: In radiolabelled ADME studies in rats and dogs, patiromer was excreted in the feces.

Special Populations and Conditions

No data are available.

10 STORAGE, STABILITY AND DISPOSAL

Store and transport refrigerated (2°C – 8°C).

After dispensing, Veltassa may be stored at room temperature (15°C to 25°C) for up to 6 months. When dispensing the product, include the discard date in the space provided on the carton.

For either storage condition, Veltassa should not be used after the expiry date printed on the sachet.

Avoid exposure to excessive heat above 40°C.

The reconstituted mixture should be kept at room temperature (15°C to 25°C) and taken within 1 hour of initial suspension.

Keep out of reach and sight of children.

11 SPECIAL HANDLING INSTRUCTIONS

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

PART II: SCIENTIFIC INFORMATION

12 PHARMACEUTICAL INFORMATION

Drug Substance


Common name: Patiromer sorbitex calcium

Chemical name: Calcium, hydrolyzed divinylbenzene-Me 2-fluoro-2-propenoate-1,7-octadiene polymer sorbitol complexes

Molecular formula: $(\text{Ca}_2\text{C}_6\text{H}_{14}\text{O}_6)_m(\text{C}_3\text{H}_2\text{FO}_2)_{4m}(\text{C}_{10}\text{H}_{10})_{4n}(\text{C}_8\text{H}_{14})_{4p}$

Molecular mass: Patiromer sorbitex calcium is a cross-linked polymer and does not have a defined molecular mass. Each polymer bead is one macromolecule that has multiple covalent crosslinks between polymer chains. The molecular weight of a 100 micrometer polymer bead is approximately 5.6×10^{17} g/mol.

Structural formula:



m = number of 2-fluoro-2-propenoate groups $m = 0.91$
 n, p = number of crosslinking groups $n + p = 0.09$
* H_2O = associated water
* = indicates an extended polymeric network

Physicochemical properties: off-white to light brown powder; insoluble in water, 0.1 M HCl, methanol and n-heptane

The sorbitol content is approximately 4 g (10.4 kcal) per 8.4 g of patiromer.

13 CLINICAL TRIALS

13.1 Trial Design and Study Demographics

Table 6 – Summary of patient demographics for clinical trials in treatment of hyperkalemia

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n) ¹	Mean age (Range) ¹	Sex ¹
RLY5016-301	Part A: Single blind, single arm Phase 3 study in subjects with hyperkalemia and CKD on stable doses of at least one RAASi – treatment phase	Group 1 (serum potassium of 5.1 to < 5.5 mmol/L) starting dose: 8.4 g patiromer orally daily (as a divided dose); Group 2 (serum potassium of 5.5 to < 6.5 mmol/L) starting dose: 16.8 g patiromer orally daily (as a divided dose); Doses of both groups were titrated to achieve and maintain serum potassium within a target range of 3.8 to < 5.1 mmol/L. 4 weeks	243	64 years (29 to 80 years)	M: 140 F: 103
	Part B: Single blind, randomized, placebo-controlled Phase 3 study in subjects with hyperkalemia and CKD on stable doses of at least one RAASi – withdrawal phase	Eligible subjects from Part A were randomized equally to either: (1) continue patiromer at the same daily dose as administered at the time of the Part A Week 4 visit; or (2) withdraw (i.e., discontinue) patiromer and receive placebo. 8 weeks following completing Part A.	107	65 years (32 to 80 years)	M: 58 F: 49

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n) ¹	Mean age (Range) ¹	Sex ¹
RLY5016-205	Phase 2, multicenter, randomized, open-label, dose-ranging study in treating hyperkalemia in hypertensive subjects with nephropathy due to Type 2 diabetes mellitus (T2DM) receiving ACEI and/or ARB drugs, with or without spironolactone	Starting doses 8.4 to 33.6 g/day patiromer orally. Doses were titrated to achieve and maintain serum potassium within a target range. Stratum 1 (serum potassium of >5.0 to 5.5 mmol/L) starting dose: 8.4 g, 16.8 g, or 25.2 g patiromer orally daily (as a divided dose); Stratum 2 (serum potassium of > 5.5 to < 6.0 mmol/L) starting dose: 16.8 g, 25.2 g, or 33.6 g patiromer orally daily (as a divided dose) Treatment Initiation Period: 8 weeks, followed by a Long-term Maintenance Period for an additional 44 weeks; total of 52 weeks.	304	66 years (37 to 80 years)	M: 192 F: 112

RAASi = renin-angiotensin-aldosterone system inhibitor (i.e., angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or aldosterone antagonist)

1. Intent-to-treat (ITT) population

In Part A of the RLY5016-301 study, eligible subjects had CKD (eGFR \geq 15 mL/min/1.73 m² and < 60 mL/min/1.73m²), were receiving a stable dose of at least one RAASi (angiotensin converting-enzyme inhibitor [ACEI], angiotensin II receptor blocker [ARB] or aldosterone antagonist [AA]), and had serum potassium levels of 5.1 to < 6.5 mmol/L. 58% of patients were male, and 98% were Caucasian. Approximately 97% had hypertension, 57% had type 2 diabetes, and 42% had heart failure. Fifty-four percent (54%) of patients were aged 65 years and over, and 17% aged 75 years and over.

In Part B of the RLY50 16-301 study, demographics were similar in the placebo and Veltassa groups. All patients were Caucasian, and approximately 97% had hypertension, 63% had type 2 diabetes, and 46% had heart failure. Fifty-six percent (56%) of patients were aged 65 years and over, and 17% aged 75 years and over in Part B.

In study RLY5016-205, eligible subjects had been diagnosed with Type 2 diabetes mellitus, had CKD (eGFR \geq 15 mL/min/1.73 m² and < 60 mL/min/1.73m²), were receiving RAASi (angiotensin converting-enzyme inhibitor [ACEI] and/or angiotensin II receptor blocker [ARB]), and had serum potassium levels of > 5.0 to < 6.0 mmol/L. There were no statistically significant differences in distribution of males and females or mean age between starting dose groups

within each stratum. The majority of subjects (60%) were 65 years of age or older, with 20% 75 years of age or older, and all subjects were of Caucasian descent.

Overall, in the clinical studies mentioned above, all patients were receiving RAASi therapy at baseline.

13.2 Study Results

Study RLY5016-301

This study was a two-part, single-blind, randomised, withdrawal study evaluating the effect of Veltassa in hyperkalemic patients with CKD on stable doses of at least one RAASi (i.e., angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or aldosterone antagonist).

Results for the Part A primary endpoint, the change in serum potassium from Baseline to Week 4, are summarized in Table 7. For the Part A secondary endpoint, 76% (95% CI: 70%, 81%) of patients had a serum potassium in the target range of 3.8 mmol/L to < 5.1 mmol/L at Week 4. The mean daily doses of Veltassa were approximately 13 grams and 21 grams in patients with serum potassium of 5.1 to < 5.5 mmol/L and 5.5 to < 6.5 mmol/L, respectively.

Table 7 – Results of study RLY5016-301 Part A in treatment of hyperkalemia

Baseline		Week 4		
Serum potassium stratum	Mean serum potassium ¹ (±SE)	Mean serum potassium ² (±SE)	Mean change from baseline [95% CI]	p-value
5.1 to < 5.5 mmol/L (n=90) ³	5.32 ± 0.061	4.66 ± 0.049	-0.65 [-0.74; -0.55]	--
5.5 to < 6.5 mmol/L (n=147) ³	5.74 ± 0.032	4.51 ± 0.040	-1.23 [-1.31; -1.16]	--
Overall Population (n=237)¹	5.58 ± 0.033	4.57 ± 0.031	-1.01 [-1.07; -0.95]	< 0.001

¹ Anova model

² Repeated measures model

³ Subjects enrolled into the Part A Treatment Phase who i) received at least one dose of RLY5016 FOS and ii) had either a central or local laboratory serum potassium result at Part A Baseline and at least one post-baseline weekly visit (i.e., Part A Week 1 or later)

The Part B primary endpoint was the change in serum potassium from Part B baseline to the earliest visit at which the patient's serum potassium was first outside of the range of 3.8 to < 5.5 mmol/L, or to Part B Week 4 if the patient's serum potassium remained within the range. In Part B, serum potassium rose by 0.72 mmol/L in patients who were switched to placebo, versus no change in patients who remained on Veltassa (Table 8). In patients randomized to Veltassa, the mean daily dose was 21 grams at the start of Part B and during Part B.

Table 8 – Results of study RLY5016-301 Part B in treatment of hyperkalemia

	Placebo (n=52)	Veltassa (n=55)	Difference	
			Estimate (95% CI)	p-value
Estimated Median Change in Serum Potassium from Baseline (mmol/L)	0.72	0.00	0.72 (0.46; 0.99)	< 0.001

More placebo patients (91%, 95% CI: 83%; 99%) developed a serum potassium ≥ 5.1 mmol/L at any time during Part B than Veltassa patients (43%, 95% CI: 30%; 56%), $p < 0.001$. More placebo patients (60%, 95% CI: 47%; 74%) developed a serum potassium ≥ 5.5 mmol/L at any time during Part B than Veltassa patients (15%, 95% CI: 6%; 24%), $p < 0.001$.

The potential of Veltassa to enable concomitant RAASi treatment was also assessed in Part B. Fifty-two percent (52%) of subjects receiving placebo discontinued RAASi treatment because of recurrent hyperkalemia compared with 5% of subjects treated with Veltassa.

Study RLY5016-205

This was an up to 52 week open-label study evaluating the effect of treatment with Veltassa in 304 hyperkalemic patients with CKD and type 2 diabetes mellitus on stable doses of a RAASi.

The primary efficacy parameter was the change in serum potassium from baseline to week 4 or prior to initiation of dose titration. Results are summarized in [Table 9](#).


Table 9 – Results of study RLY5016-205 in treatment of hyperkalemia

Baseline		Week 4 ¹		
Serum potassium stratum	Mean serum potassium (\pm SE)	Mean serum potassium (\pm SE)	Mean change from baseline [95% CI]	p-value
> 5.0 to 5.5 mmol/L (n=220)	5.15 \pm 0.017	4.68 \pm 0.039	-0.47 [-0.55; -0.40]	< 0.001
> 5.5 to < 6.0 mmol/L (n=84)	5.66 \pm 0.039	4.74 \pm 0.073	-0.92 [-1.07; -0.77]	< 0.001

¹ For subjects who required Veltassa dose titration before Week 4, the endpoint is the last observed data prior to the first titration. For subjects who prematurely discontinued Veltassa without dose titration and prior to Week 4, the endpoint was the last observed post-baseline data prior to termination.

Decreases in serum potassium with Veltassa treatment were maintained over 1 year of chronic treatment as shown in Figure 1, with a low incidence of hypokalemia (2.3%). A majority of subjects (97.7%) reached the target serum potassium range (4.0–5.0 mmol/L) during the 8 week treatment initiation period and maintained target levels (3.8 to 5.0 mmol/L) during the long-term (up to 44 week) maintenance period (overall during maintenance period, serum potassium was within the target range for approximately 80% of the time). In patients with a baseline serum potassium of >5.0 to 5.5 mmol/L who received an initial dose of 8.4 g patiromer per day, the mean daily dose was 14 g; in those with a baseline serum potassium of >5.5 to <6.0 mmol/L who received an initial dose of 16.8 g patiromer per day, the mean daily dose was 20 g during the entire study.

Figure 1 – MEAN (95% CI) SERUM POTASSIUM OVER TIME



Number of Subjects:																				
Lower K ⁺ Stratum:	218	199	192	175	168	161	161	163	158	156	151	148	149	145	131	126				
Higher K ⁺ Stratum:	83	73	70	65	62	62	62	61	53	53	53	52	49	49	48	47				

14 NON-CLINICAL TOXICOLOGY

General Toxicity

No single-dose toxicity studies were conducted. A 26 week repeat-dose toxicity study in rats showed no dose-dependent clinical signs of toxicity, ophthalmic findings, or effects on mean body weight or body weight changes that could be associated with the drug, at doses ranging from 1 to 5 g/kg/day. The NOAEL of 5 g/kg/day provides a 10-fold safety margin. A 39-week repeat dose toxicity study in beagle dogs with doses ranging from 1 to 3.75 g/kg/day resulted in no drug-related mortalities, ophthalmic or cardiovascular observations, and no adverse effects on body weight, food consumption, or macroscopic or microscopic changes. Certain sex-specific effects observed (such as serum potassium reduction and gastrointestinal events) were difficult to interpret due to limited statistical power, and were not observed subsequently in clinical studies. The NOAEL in this study was 3.75 g/kg/day. This provides a 7-fold safety margin.

In radiolabeled studies in rats and dogs, patiromer was not systemically absorbed and was excreted in the feces. Quantitative whole-body autoradiography analysis in rats demonstrated

that radioactivity was limited to the gastrointestinal tract, with no detectable level of radioactivity in any other tissues or organs.

Carcinogenicity

Carcinogenicity studies have not been performed.

Genotoxicity

Patiromer was not genotoxic in the reverse mutation test (Ames assay), chromosome aberration or rat micronucleus assays.

Reproductive and Developmental Toxicity

Animal studies showed no significant effects on reproductive function or fertility at doses up to 1 times the maximum recommended human dose (MRHD). However, mean sperm motility and velocity were lower with higher doses, and levels were at or below historical controls for all tests at the highest drug dose. While this did not lead to significantly reduced fertility rates in rats, similar changes in humans might be associated with reduced fertility. Patiromer also did not statistically significantly affect embryo-fetal development in pregnant rats at dose levels up to 6 g/kg, providing up to a 12-fold margin above the MRHD, and in pregnant rabbits at dose levels up to 3 g/kg, providing up to a 6-fold margin above the MRHD. However, offspring were not followed after birth to confirm whether prenatal exposure had lasting post-natal effects. The evidence provided does not confirm the absence of an indirect effect on offspring health as a result of maternal patiromer exposure.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION

VELTASSA

Patiromer Powder for Oral Suspension

Read this carefully before you start taking **Veltassa** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Veltassa**.

What is Veltassa used for?

Veltassa is used to treat high amounts of potassium in the blood. Veltassa is only for use in patients with chronic kidney disease, except for end stage kidney disease.

How does Veltassa work?

Veltassa attaches to potassium in the intestine, so less potassium is absorbed into your blood. Veltassa starts working within about 4 to 7 hours.

What are the ingredients in Veltassa?

Medicinal ingredients: patiromer as patiromer sorbitex calcium

Non-medicinal ingredients: xanthan gum

Veltassa contains sorbitol and calcium. The sorbitol content is about 4 g (10.4 kcal) per 8.4 g of patiromer.

Veltassa comes in the following dosage forms:

Powder for oral suspension in sachets containing 8.4 g, 16.8 g, or 25.2 g patiromer.

Do not use Veltassa if:

- you are allergic to patiromer or any other ingredients in Veltassa.
- you have fructose intolerance because Veltassa contains sorbitol.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Veltassa. Talk about any health conditions or problems you may have, including if you:

- have problems swallowing.
- have severe stomach or bowel problems.
- had major surgery on your stomach or bowel.
- are pregnant or nursing, or think you may be pregnant or are planning to have a baby. It is not known if Veltassa may be harmful to the fetus while you are pregnant or to your nursing baby.
- know you have a high level of calcium in your blood or you are taking calcium supplements.

Other warnings you should know about:

- Low blood magnesium can occur when taking Veltassa. Your healthcare professional will check your magnesium level during at least the first month of treatment with Veltassa and may prescribe a magnesium supplement.
- Your healthcare professional may monitor your potassium levels while you are taking Veltassa. If your potassium levels drop too low, your dose of Veltassa may be lowered

- or you may be told to stop taking Veltassa.
- Do not stop taking Veltassa without your healthcare professional's approval, as your potassium blood level may increase.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Take all oral medicines (taken by mouth) at least 3 hours before or after you take Veltassa, unless your healthcare professional gives you different advice. Ask your healthcare professional if you are not sure.

The following may interact with Veltassa:

- ciprofloxacin
- levothyroxine
- metformin
- quinidine
- thiamine

How to take Veltassa:

Always take this medicine exactly as your healthcare professional has told you. Check with your healthcare professional if you are not sure.

Mix Veltassa with water and stir until it is thoroughly mixed, as follows:

- Prepare about 40 mL (3 tablespoons) of water in a glass.
- Add the required number of Veltassa sachets and stir.
- Add about 40 mL (3 tablespoons) of additional water and stir thoroughly. The powder does not dissolve but forms a suspension.
- You may add more water to the mixture to help you swallow the medicine.
- Drink the mixture within 1 hour after preparation and keep the mixture at room temperature. If powder remains in the glass after drinking, add more water, stir and drink immediately. You may need to do this again to make sure that you have taken all the powder.

You can use apple juice or cranberry juice instead of water. Other liquids cannot be used as they may contain high amounts of potassium.

Take the prepared Veltassa suspension preferably at the same time each day, with or without food. Never heat Veltassa or add it to hot foods or liquids.

Do not take Veltassa as a dry powder.

Usual dose:

- Starting dose: 8.4 g patiromer (the content of one 8.4 g sachet) once daily
- Maximum dose: 25.2 g patiromer once daily

Your healthcare professional may adjust the dose depending on the potassium level in your blood.

Take Veltassa at least 3 hours before or after other medicines taken by mouth unless your healthcare professional gives you different advice.

Overdose:

If you think you have taken too much Veltassa, stop taking Veltassa and contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you missed a dose of Veltassa, take it as soon as you remember on the same day. But if it is almost time for your next dose, skip the missed dose and continue with your next scheduled dose. Go back to the regular dosing schedule. Do not take two doses at the same time. If you miss more than one dose, contact your healthcare professional.

What are possible side effects from using Veltassa?

These are not all the possible side effects you may feel when taking Veltassa. If you experience any side effects not listed here, contact your healthcare professional.

Most of the side effects with Veltassa occur within the first 4 weeks of treatment.

- Common side effects (up to 1 in 10 people) include constipation, diarrhea, abdominal pain, low blood levels of potassium or magnesium and gas.
- Uncommon side effects (up to 1 in 100 people) include the following:
 - Stomach bloating, indigestion, upper abdomen discomfort, acid reflux, nausea and vomiting.
 - Allergic reactions such as swelling.
 - Anorexia.
 - Muscle cramping.
 - Altered sense of food taste.
 - Skin itching.
 - Low blood levels of iron or phosphorus.
 - Low blood pressure.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Once you receive Veltassa, it can be stored at room temperature between 15°C to 25°C for up to 6 months.
- Veltassa should not be used after the expiry date printed on the sachet, or after the discard date written on the carton by the pharmacist (whichever comes first). The expiry date refers to the last day of that month.
- Avoid exposure to excessive heat above 40°C.
- Keep out of reach and sight of children.
- Do not throw away any medicines via wastewater or household waste. Ask your healthcare professional how to throw away medicines you no longer use. These measures will help protect the environment.

If you want more information about Veltassa:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>); or by calling 1-877-341-9245.

This leaflet was prepared by Vifor Fresenius Medical Care Renal Pharma Ltd.

Last Revised February 28, 2020